Sumitomo Pharma (OTCMKTS:DNPUF – Get Free Report) is expected to announce its results after the market closes on Friday, October 30th. Analysts expect the company to post earnings of $0.1791 per share and revenue of $842.06 million for the quarter.
Sumitomo Pharma Price Performance
OTCMKTS DNPUF opened at $11.91 on Wednesday. Sumitomo Pharma has a 12 month low of $8.40 and a 12 month high of $19.20. The company has a 50-day moving average of $9.71 and a 200-day moving average of $11.06.
Sumitomo Pharma Company Profile
Sumitomo Pharma Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Its activities focus primarily on central nervous system disorders, including psychiatric and neurological conditions, as well as oncology, metabolic diseases and other areas of unmet medical need.
The company’s portfolio has included medicines for schizophrenia, bipolar disorder, depression and Parkinson’s disease, along with treatments in other specialty-care categories.
Read More
- Five stocks we like better than Sumitomo Pharma
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Sumitomo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sumitomo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
